We are monitoring the impact of COVID-19 & Recession alarm on ADHD Therapeutics Market Get in touch with us for detailed analysis Know More
Share on

Global ADHD Therapeutics Market Size, Share, Trends, COVID-19 Impact & Growth Analysis Report – Segmented Based on Treatment by Medication, Psychotherapy, Education or Training and Region - Industry Forecast (2022 to 2027)

Published: January, 2022
ID: 264
Pages: 175

ADHD Therapeutics Market Size (2022 to 2027)

The global attention deficit hyperactivity disorder therapeutics market size is to reach USD 45.68 billion by 2027 from USD 29.56 billion in 2022. The market is expected to be growing at a CAGR of 9.09% during the forecast period. 

Attention deficit hyperactivity is a neurodevelopmental disorder that damages and envelops symptoms of impulsivity and hyperactivity. Treating and controlling the disease with the help of technology defines neurobehavioral because of the way the brain affects learning, behavior, and emotion. 

MARKET DRIVERS:

Y-O-Y rise in the incidence of attention deficit hyperactivity disorder across the world is driving the global ADHD therapeutics market growth.

The causes of ADHD are still indistinct, although genetic presence is observed in many cases. As per the data given by the Centre for Disease Control and Prevention (CDC) in 2016, around 6.1 million individuals, including 388,000 children aged 2–5 years, 4 million 6–11 years, and 3 million 12–17 years, were diagnosed with ADHD in the U.S. besides, boys are more likely to be diagnosed than girls. 

The frequency of ADHD is rising at a higher rate, which drives the global attention-deficit hyperactivity disorder therapeutics market, as there is no treatment for this disorder. Furthermore, the ADHD therapeutics market is mainly driven by the rough impact of unstable lifestyles and additives in children's diets, increasing the incidence of ADHD within the 4-to-17-year age group. Moreover, increasing awareness concerning syndrome among physicians and patients and opinion-based due to the lack of regular diagnostic tests is anticipated to fuel revenue growth of the worldwide ADHD market in the coming future.

Additionally, increasing advancements in the medical field, a growing number of research in neurosciences, and raising awareness about mental illness among people are fuelling the market growth to a considerable extent. Furthermore, expanding the focus of biotechnology & pharmaceutical companies into developing innovative therapeutics for ADHD drives the development of the global ADHD therapeutics market.

MARKET RESTRAINTS:

The high cost of ADHD medications, improper reimbursement policies, and side effects related to ADHD medications (such as insomnia, anorexia, dizziness, headaches, and mood changes) are restraining the growth of the global ADHD therapeutics market. In addition, all the side effects associated with ADHD drugs affect the patients' lives and hamper the revenue growth of the attention-deficit hyperactivity disorder therapeutics market in the given forecast period. In addition, problems like allergic reactions to medicine, medical conditions like coronary artery disease, kidney disease, and seizures are associated with attention deficit hyperactivity disorder medicines.

Impact of COVID-19 on the global ADHD therapeutics market:

COVID-19 has had a lot of negative impacts on people suffering from attention-deficit hyperactivity disorder. The main reason for the effect is vulnerability to the distress caused by the pandemic and physical distancing measures. Due to these factors, the patient can showcase increased behavioral problems. The increase in the issues will boost the sale of ADHD therapeutics, and the panic buying by consumers has finished the stock of the current batch of medicines and forced them to make a new batch. In addition, hospital visits for non-essential medical conditions have been postponed, causing individuals with ADHD to rely solely on drugs.

REPORT COVERAGE:

REPORT METRIC

DETAILS

Market Size Available

2021 to 2027

Base Year

2021

Forecast Period

2022 to 2027

Segments Covered

By Type, Production Technologies, and Region

Various Analyses Covered

Global, Regional & Country Level Analysis, Segment-Level Analysis, Drivers, Restraints, Opportunities, Challenges, PESTLE Analysis, Porter’s Five Forces Analysis, Competitive Landscape, Analyst Overview on Investment Opportunities

Regions Covered

North America, Europe, Asia Pacific, Latin America, Middle East & Africa

 

This research report on the global attention deficit hyperactivity disorder therapeutics market has been segmented and sub-segmented based on the Type, Production Technologies, and Region. 

ADHD Therapeutics Market - Treatment by Medication:

  • Stimulants
    • Amphetamines 
    • Methylphenidate       
    • Dextroamphetamine    
    • Dexmethylphenidate   
  • Non-Stimulants
    • Atomoxetine    
    • Bupropion      
    • Guanfacine    

Based on the medication types, stimulants are expected to emerge as the drugs of choice among physicians and patients worldwide. Amphetamine is also to gain popularity over the forecast period.  

Stimulants lead the market and are expected to grow at a promising rate from 2022 to 2027. Around 70-80% of children who have ADHD use stimulants as medication to treat the disease. These stimulants help cure ADHD. In addition, these drugs act as a stimulant for the central nervous system. The most common stimulant used is Concerta (methylphenidate), Dexedrine (amphetamine), and Evekeo (amphetamine).

Non stimulants accounted for the second market share in 2021, and with the rise in cases, the growth expected is positive in the future. These drugs are used to treat ADHD and are taken with stimulants and alone. Atomoxetine is recommended for patients above six years.

ADHD Therapeutics Market - Treatment by Psychotherapy:

  • Behaviour Therapy
  • Cognitive Behavioral Therapy
  • Interpersonal Psychotherapy
  • Family Therapy

Based on the psychotherapy treatment type, the Behavior therapy segment is the most commonly used method for ADHD treatment. It is an effective treatment that can help children improve their self-esteem, behavior, and self-control. It is primarily helpful with the stimulant medication going on, and with time, we can see a reduction in drug dosage.

Interpersonal psychotherapy is a time-limited and focused approach to treating mood disorders. Its popularity is increasing daily and is very effective in treating ADHD.

Family therapy is very effective in treating ADHD, and its popularity is increasing daily.

ADHD Therapeutics Market - Treatment by Education or Training:

  • Parent Management Training
  • Social Skills Training
  • School-Based Interventions

Parent Management Training is most popular among others. It is incredibly efficient in treating ADHD, and the rising awareness about its effectiveness will further drive its market.

Social skills training by schools and experts is also very effective in treating ADHD. Schools based intervention method is also being used more to treat ADHD, and with the rising cases, the method will increase quickly.

ADHD Therapeutics Market – By Region:

  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East and Africa

Geographically, the North America ADHD therapeutics market commanded a share of 36.0% of the global market in 2021. The growth of the North American market is driven by the growing rate of patients with attention deficit hyperactivity disorder and high healthcare expenditure. It is the reason behind the large revenue pocket of the local market in the U.S. Therefore, and the region would hold its leading position in the global attention deficit hyperactivity disorder therapeutics market in the forecast period. 

The Europe ADHD therapeutics market held the second-most position in the global market in 2021, along with emerging technology and digital medicines. The affluent medical device market and growing healthcare expenditure are responsible for the market's growth. 

The Asia Pacific ADHD therapeutics market is growing at a CAGR of 12.3% from 2022 to 2027. The factors responsible for the market's growth are the unmet needs and sizeable patient population, and even the availability of lower-cost drugs for ADHD treatment. Moreover, improving the economy in the region is acting as a key to the success of pushing up the regional market and boosting the healthcare sector. Private organizations and the increased funding from the population are responsible for the regional market's growth. In addition, the explosion of healthcare insurance in many countries like Malaysia, Thailand, and Vietnam is expected to drive the ADHD market in the Asia Pacific. Also, the availability of the new treatments and the technology affect the growing demand and propel the growth of the regional ADHD therapeutics market.

The Latin America ADHD therapeutics market is estimated to be worth USD 1.53 billion by 2027. On the other hand, the ADHD therapeutics market in the Middle East and Africa is predicted to grow at a CAGR of 9.31% from 2022 to 2027.

KEY MARKET PARTICIPANTS:

Some of the key market players dominating the global ADHD therapeutics market profiled in the report are Shire plc (Ireland), Neos Therapeutics, Inc. (U.S.), Eli Lilly and Company (U.S.), Pfizer Inc. (U.S.), Alcobra Ltd. (Israel), Supernus Pharmaceuticals, Inc. (U.S.), Noven Pharmaceuticals, Inc. (U.S.), Novartis AG (Switzerland), Johnson & Johnson (U.S.) and Curemark, LLC. (U.S.).

  1. Introduction

                1.1 Market Definition                                    

                1.2 Study Deliverables                                  

                1.3 Base Currency, Base Year and Forecast Periods                                          

                1.4 General Study Assumptions                                

  1. Research Methodology

                2.1 Introduction                                               

                2.2 Research Phases                                      

                                2.2.1 Secondary Research                           

                                2.2.2 Primary Research                 

                                2.2.3 Econometric Modelling                      

                                2.2.4 Expert Validation                  

                2.3 Analysis Design                                         

                2.4 Study Timeline                                          

  1. Overview

                3.1 Executive Summary                                

                3.2 Key Inferences                                         

                3.3 New Developments                                               

  1. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)

                4.1 Market Drivers                                          

                4.2 Market Restraints                                    

                4.3 Key Challenges                                         

                4.4 Current Opportunities in the Market                                              

  1. Market Segmentation

                5.1 Introduction                                               

                5.2 Treatment By Medication                                    

                                5.2.1 Introduction                           

                                5.2.2 Stimulants                               

                                                5.2.2.1 Introduction       

                                                5.2.2.2 Amphetamines 

                                                5.2.2.3 Methylphenidate             

                                                5.2.2.4 Dextroamphetamine      

                                                5.2.2.5 Dexmethylphenidate     

                                5.2.3 Non-Stimulants                     

                                                5.2.3.1 Introduction       

                                                5.2.3.2 Atomoxetine      

                                                5.2.3.3 Bupropion           

                                                5.2.3.4 Guanfacine         

                5.3 Treatment By Psychotherapy                                             

                                5.3.1 Introduction                           

                                5.3.2 Behavior Therapy                 

                                5.3.3 Cognitive Behavioral Therapy                         

                                5.3.4 Interpersonal Psychotherapy                         

                                5.3.5 Family Therapy                      

                5.4 Treatment By Education or Training                                 

                                5.3.1 Introduction                           

                                5.3.2 Parent Management Training                         

                                5.3.3 Social Skills Training                             

                                5.3.4 School-Based Interventions                            

  1. Geographical Analysis

                6.1 North America                                          

                                6.1.1 Introduction                           

                                6.1.2 United States                         

                                6.1.3 Canada                     

                6.2 Europe                                         

                                6.2.1 Introduction                           

                                6.2.2 U.K                             

                                6.2.3 Spain                         

                                6.2.4 Germany                 

                                6.2.5 Italy                            

                                6.2.6 France                       

                6.3 Asia-Pacific                                 

                                6.3.1 Introduction                           

                                6.3.2 China                         

                                6.3.3 India                          

                                6.3.4 Japan                         

                                6.3.5 Australia                   

                                6.3.6 Soth Korea                              

                6.4 Latin America                                             

                                6.4.1 Introduction                           

                                6.4.2 Brazil                          

                                6.4.3 Argentina                

                                6.4.4 Mexico                     

                6.5 Middle East & Africa                                               

                                6.5.1 Introduction                           

                                6.5.2 Middle East                             

                                6.5.3 South Africa                            

  1. Strategic Analysis

                7.1 PESTLE analysis                                         

                                7.1.1 Political                     

                                7.1.2 Economic                 

                                7.1.3 Social                         

                                7.1.4 Technological                         

                                7.1.5 Legal                          

                                7.1.6 Environmental                       

                7.2 Porter’s Five analysis                                              

                                7.2.1 Bargaining Power of Suppliers                        

                                7.2.2 Bargaining Power of Consumers                    

                                7.2.3 Threat of New Entrants                     

                                7.2.4 Threat of Substitute Products and Services                              

                                7.2.5 Competitive Rivalry within the Industry                     

  1. Market Leaders' Analysis

                8.1 Shire plc (Ireland)                                    

                                8.1.1 Overview                 

                                8.1.2 Product Analysis                   

                                8.1.3 Strategic Evaluation and Operations                            

                                8.1.4 Financial analysis                  

                                8.1.5 Legal issues                             

                                8.1.6 Recent Developments                       

                                8.1.7 SWOT analysis                       

                                8.1.8 Analyst View                          

                8.2 Neos Therapeutics, Inc. (U.S.)                                            

                8.3 Eli Lilly and Company (U.S.)                                  

                8.4 Pfizer Inc. (U.S.)                                       

                8.5 Alcobra Ltd. (Israel)                                 

                8.6 Supernus Pharmaceuticals, Inc. (U.S.)                                            

                8.7 Noven Pharmaceuticals, Inc. (U.S.)                                  

                8.8 Novartis AG (Switzerland)                                    

                8.9 Johnson & Johnson (U.S.)                                    

                8.10 Curemark, LLC., (U.S.)                                         

  1. Competitive Landscape

                9.1 Market share analysis                                            

                9.2 Merger and Acquisition Analysis                                       

                9.3 Agreements, collaborations and Joint Ventures                                         

                9.4 New Product Launches                                         

  1. Expert Opinions

                10.1 Market Outlook                                     

                10.2 Investment Opportunities                                 

     Appendix                                                          

a) List of Tables

b) List of Figures

  1. Global ADHD Therapeutics Market, By Region, From 2027 to 2027 (USD Billion)
  2. Global ADHD Therapeutics Market, By Medication, From 2027 to 2027 (USD Billion)
  3. Global Stimulants Market, By Region, From 2027 to 2027 (USD Billion)
  4. Global Non-Stimulants Market, By Region, From 2027 to 2027 (USD Billion)
  5. Global ADHD Therapeutics Market, By Psychotherapy, From 2027 to 2027 (USD Billion)
  6. Global Behaviour Therapy ADHD Therapeutics Market, By Region, From 2027 to 2027 (USD Billion)
  7. Global Cognitive Behavioral Therapy ADHD Therapeutics Market, By Region, From 2027 to 2027 (USD Billion)
  8. Global Interpersonal Psychotherapy ADHD Therapeutics Market, By Region, From 2027 to 2027 (USD Billion)
  9. Global Family Therapy ADHD Therapeutics Market, By Region, From 2027 to 2027 (USD Billion)
  10. Global ADHD Therapeutics Market, By Education or Training, From 2027 to 2027 (USD Billion)
  11. Global Parent Management Training ADHD Therapeutics Market, By Region, From 2027 to 2027 (USD Billion)
  12. Global Social Skills Training ADHD Therapeutics Market, By Region, From 2027 to 2027 (USD Billion)
  13. Global School-based Interventions ADHD Therapeutics Market, By Region, From 2027 to 2027 (USD Billion)
  14. Global Stimulants ADHD Therapeutics Market, By Type, From 2027 to 2027 (USD Billion)
  15. Global Amphetamines Market, By Region, From 2027 to 2027 (USD Billion)
  16. Global Methylphenidate Market, By Region, From 2027 to 2027 (USD Billion)
  17. Global Dextroamphetamine Market, By Region, From 2027 to 2027 (USD Billion)
  18. Global Dexmethylphenidate Market, By Region, From 2027 to 2027 (USD Billion)
  19. Global Non-Stimulants ADHD Therapeutics Market, By Type, From 2027 to 2027 (USD Billion)
  20. Global Atomoxetine Market, By Region, From 2027 to 2027 (USD Billion)
  21. Global Bupropion Market, By Region, From 2027 to 2027 (USD Billion)
  22. Global Guanfacine Market, By Region, From 2027 to 2027 (USD Billion)
  23. North America ADHD Therapeutics Market, By Region, From 2027 to 2027 (USD Billion)
  24. North America ADHD Therapeutics Market, By Medication, From 2027 to 2027 (USD Billion)
  25. North America Stimulants Market, By Region, From 2027 to 2027 (USD Billion)
  26. North America Non-Stimulants Market, By Region, From 2027 to 2027 (USD Billion)
  27. North America ADHD Therapeutics Market, By Psychotherapy, From 2027 to 2027 (USD Billion)
  28. North America Behavior Therapy ADHD Therapeutics Market, By Region, From 2027 to 2027 (USD Billion)
  29. North America Cognitive Behavioral Therapy ADHD Therapeutics Market, By Region, From 2027 to 2027 (USD Billion)
  30. North America Interpersonal Psychotherapy ADHD Therapeutics Market, By Region, From 2027 to 2027 (USD Billion)
  31. North America Family Therapy ADHD Therapeutics Market, By Region, From 2027 to 2027 (USD Billion)
  32. North America ADHD Therapeutics Market, By Education or Training, From 2027 to 2027 (USD Billion)
  33. North America Parent Management Training ADHD Therapeutics Market, By Region, From 2027 to 2027 (USD Billion)
  34. North America Social Skills Training ADHD Therapeutics Market, By Region, From 2027 to 2027 (USD Billion)
  35. North America School-based Interventions ADHD Therapeutics Market, By Region, From 2027 to 2027 (USD Billion)
  36. United States ADHD Therapeutics Market, By Medication, From 2027 to 2027 (USD Billion)
  37. United States ADHD Therapeutics Market, By Psychotherapy, From 2027 to 2027 (USD Billion)
  38. United States ADHD Therapeutics Market, By Education or Training, From 2027 to 2027 (USD Billion)
  39. Canada ADHD Therapeutics Market, By Medication, From 2027 to 2027 (USD Billion)
  40. Canada ADHD Therapeutics Market, By Psychotherapy, From 2027 to 2027 (USD Billion)
  41. Canada ADHD Therapeutics Market, By Education or Training, From 2027 to 2027 (USD Billion)
  42. North America Stimulants ADHD Therapeutics Market, By Type, From 2027 to 2027 (USD Billion)
  43. North America Amphetamines Market, By Region, From 2027 to 2027 (USD Billion)
  44. North America Methylphenidate Market, By Region, From 2027 to 2027 (USD Billion)
  45. North America Dextroamphetamine Market, By Region, From 2027 to 2027 (USD Billion)
  46. North America Dexmethylphenidate Market, By Region, From 2027 to 2027 (USD Billion)
  47. United States Stimulants ADHD Therapeutics Market, By Type, From 2027 to 2027 (USD Billion)
  48. Canada Stimulants ADHD Therapeutics Market, By Type, From 2027 to 2027 (USD Billion)
  49. North America Non-Stimulants ADHD Therapeutics Market, By Type, From 2027 to 2027 (USD Billion)
  50. North America Atomoxetine Market, By Region, From 2027 to 2027 (USD Billion)
  51. North America Bupropion Market, By Region, From 2027 to 2027 (USD Billion)
  52. North America Guanfacine Market, By Region, From 2027 to 2027 (USD Billion)
  53. United States Non-Stimulants ADHD Therapeutics Market, By Type, From 2027 to 2027 (USD Billion)
  54. Canada Non-Stimulants ADHD Therapeutics Market, By Type, From 2027 to 2027 (USD Billion)
  55. Europe ADHD Therapeutics Market, By Region, From 2027 to 2027 (USD Billion)
  56. Europe ADHD Therapeutics Market, By Medication, From 2027 to 2027 (USD Billion)
  57. Europe Stimulants Market, By Region, From 2027 to 2027 (USD Billion)
  58. Europe Non-Stimulants Market, By Region, From 2027 to 2027 (USD Billion)
  59. Europe ADHD Therapeutics Market, By Psychotherapy, From 2027 to 2027 (USD Billion)
  60. Europe Behavior Therapy ADHD Therapeutics Market, By Region, From 2027 to 2027 (USD Billion)
  61. Europe Cognitive Behavioral Therapy ADHD Therapeutics Market, By Region, From 2027 to 2027 (USD Billion)
  62. Europe Interpersonal Psychotherapy ADHD Therapeutics Market, By Region, From 2027 to 2027 (USD Billion)
  63. Europe Family Therapy ADHD Therapeutics Market, By Region, From 2027 to 2027 (USD Billion)
  64. Europe ADHD Therapeutics Market, By Education or Training, From 2027 to 2027 (USD Billion)
  65. Europe Parent Management Training ADHD Therapeutics Market, By Region, From 2027 to 2027 (USD Billion)
  66. Europe Social Skills Training ADHD Therapeutics Market, By Region, From 2027 to 2027 (USD Billion)
  67. Europe School-based Interventions ADHD Therapeutics Market, By Region, From 2027 to 2027 (USD Billion)
  68. U.K ADHD Therapeutics Market, By Medication, From 2027 to 2027 (USD Billion)
  69. U.K ADHD Therapeutics Market, By Psychotherapy, From 2027 to 2027 (USD Billion)
  70. U.K ADHD Therapeutics Market, By Education or Training, From 2027 to 2027 (USD Billion)
  71. Spain ADHD Therapeutics Market, By Medication, From 2027 to 2027 (USD Billion)
  72. Spain ADHD Therapeutics Market, By Psychotherapy, From 2027 to 2027 (USD Billion)
  73. Spain ADHD Therapeutics Market, By Education or Training, From 2027 to 2027 (USD Billion)
  74. Germany ADHD Therapeutics Market, By Medication, From 2027 to 2027 (USD Billion)
  75. Germany ADHD Therapeutics Market, By Psychotherapy, From 2027 to 2027 (USD Billion)
  76. Germany ADHD Therapeutics Market, By Education or Training, From 2027 to 2027 (USD Billion)
  77. Italy ADHD Therapeutics Market, By Medication, From 2027 to 2027 (USD Billion)
  78. Italy ADHD Therapeutics Market, By Psychotherapy, From 2027 to 2027 (USD Billion)
  79. Italy ADHD Therapeutics Market, By Education or Training, From 2027 to 2027 (USD Billion)
  80. France ADHD Therapeutics Market, By Medication, From 2027 to 2027 (USD Billion)
  81. France ADHD Therapeutics Market, By Psychotherapy, From 2027 to 2027 (USD Billion)
  82. France ADHD Therapeutics Market, By Education or Training, From 2027 to 2027 (USD Billion)
  83. Europe Stimulants ADHD Therapeutics Market, By Type, From 2027 to 2027 (USD Billion)
  84. Europe Amphetamines Market, By Region, From 2027 to 2027 (USD Billion)
  85. Europe Methylphenidate Market, By Region, From 2027 to 2027 (USD Billion)
  86. Europe Dextroamphetamine Market, By Region, From 2027 to 2027 (USD Billion)
  87. Europe Dexmethylphenidate Market, By Region, From 2027 to 2027 (USD Billion)
  88. U.K Stimulants ADHD Therapeutics Market, By Type, From 2027 to 2027 (USD Billion)
  89. Spain Stimulants ADHD Therapeutics Market, By Type, From 2027 to 2027 (USD Billion)
  90. Germany Stimulants ADHD Therapeutics Market, By Type, From 2027 to 2027 (USD Billion)
  91. Italy Stimulants ADHD Therapeutics Market, By Type, From 2027 to 2027 (USD Billion)
  92. France Stimulants ADHD Therapeutics Market, By Type, From 2027 to 2027 (USD Billion)
  93. Europe Non-Stimulants ADHD Therapeutics Market, By Type, From 2027 to 2027 (USD Billion)
  94. Europe Atomoxetine Market, By Region, From 2027 to 2027 (USD Billion)
  95. Europe Bupropion Market, By Region, From 2027 to 2027 (USD Billion)
  96. Europe Guanfacine Market, By Region, From 2027 to 2027 (USD Billion)
  97. U.K Non-Stimulants ADHD Therapeutics Market, By Type, From 2027 to 2027 (USD Billion)
  98. Spain Non-Stimulants ADHD Therapeutics Market, By Type, From 2027 to 2027 (USD Billion)
  99. Germany Non-Stimulants ADHD Therapeutics Market, By Type, From 2027 to 2027 (USD Billion)
  100. Italy Non-Stimulants ADHD Therapeutics Market, By Type, From 2027 to 2027 (USD Billion)
  101. France Non-Stimulants ADHD Therapeutics Market, By Type, From 2027 to 2027 (USD Billion)
  102. Asia-Pacific ADHD Therapeutics Market, By Region, From 2027 to 2027 (USD Billion)
  103. Asia-Pacific ADHD Therapeutics Market, By Medication, From 2027 to 2027 (USD Billion)
  104. Asia-Pacific Stimulants Market, By Region, From 2027 to 2027 (USD Billion)
  105. Asia-Pacific Non-Stimulants Market, By Region, From 2027 to 2027 (USD Billion)
  106. Asia-Pacific ADHD Therapeutics Market, By Psychotherapy, From 2027 to 2027 (USD Billion)
  107. Asia-Pacific Behavior Therapy ADHD Therapeutics Market, By Region, From 2027 to 2027 (USD Billion)
  108. Asia-Pacific Cognitive Behavioral Therapy ADHD Therapeutics Market, By Region, From 2027 to 2027 (USD Billion)
  109. Asia-Pacific Interpersonal Psychotherapy ADHD Therapeutics Market, By Region, From 2027 to 2027 (USD Billion)
  110. Asia-Pacific Family Therapy ADHD Therapeutics Market, By Region, From 2027 to 2027 (USD Billion)
  111. Asia-Pacific ADHD Therapeutics Market, By Education or Training, From 2027 to 2027 (USD Billion)
  112. Asia-Pacific Parent Management Training ADHD Therapeutics Market, By Region, From 2027 to 2027 (USD Billion)
  113. Asia-Pacific Social Skills Training ADHD Therapeutics Market, By Region, From 2027 to 2027 (USD Billion)
  114. Asia-Pacific School-based Interventions ADHD Therapeutics Market, By Region, From 2027 to 2027 (USD Billion)
  115. China ADHD Therapeutics Market, By Medication, From 2027 to 2027 (USD Billion)
  116. China ADHD Therapeutics Market, By Psychotherapy, From 2027 to 2027 (USD Billion)
  117. China ADHD Therapeutics Market, By Education or Training, From 2027 to 2027 (USD Billion)
  118. India ADHD Therapeutics Market, By Medication, From 2027 to 2027 (USD Billion)
  119. India ADHD Therapeutics Market, By Psychotherapy, From 2027 to 2027 (USD Billion)
  120. India ADHD Therapeutics Market, By Education or Training, From 2027 to 2027 (USD Billion)
  121. Japan ADHD Therapeutics Market, By Medication, From 2027 to 2027 (USD Billion)
  122. Japan ADHD Therapeutics Market, By Psychotherapy, From 2027 to 2027 (USD Billion)
  123. Japan ADHD Therapeutics Market, By Education or Training, From 2027 to 2027 (USD Billion)
  124. South Korea ADHD Therapeutics Market, By Medication, From 2027 to 2027 (USD Billion)
  125. South Korea ADHD Therapeutics Market, By Psychotherapy, From 2027 to 2027 (USD Billion)
  126. South Korea ADHD Therapeutics Market, By Education or Training, From 2027 to 2027 (USD Billion)
  127. Australia ADHD Therapeutics Market, By Medication, From 2027 to 2027 (USD Billion)
  128. Australia ADHD Therapeutics Market, By Psychotherapy, From 2027 to 2027 (USD Billion)
  129. Australia ADHD Therapeutics Market, By Education or Training, From 2027 to 2027 (USD Billion)
  130. Asia-Pacific Stimulants ADHD Therapeutics Market, By Type, From 2027 to 2027 (USD Billion)
  131. Asia-Pacific Amphetamines Market, By Region, From 2027 to 2027 (USD Billion)
  132. Asia-Pacific Methylphenidate Market, By Region, From 2027 to 2027 (USD Billion)
  133. Asia-Pacific Dextroamphetamine Market, By Region, From 2027 to 2027 (USD Billion)
  134. Asia-Pacific Dexmethylphenidate Market, By Region, From 2027 to 2027 (USD Billion)
  135. China Stimulants ADHD Therapeutics Market, By Type, From 2027 to 2027 (USD Billion)
  136. India Stimulants ADHD Therapeutics Market, By Type, From 2027 to 2027 (USD Billion)
  137. Japan Stimulants ADHD Therapeutics Market, By Type, From 2027 to 2027 (USD Billion)
  138. South Korea Stimulants ADHD Therapeutics Market, By Type, From 2027 to 2027 (USD Billion)
  139. Australia Stimulants ADHD Therapeutics Market, By Type, From 2027 to 2027 (USD Billion)
  140. Asia-Pacific Non-Stimulants ADHD Therapeutics Market, By Type, From 2027 to 2027 (USD Billion)
  141. Asia-Pacific Atomoxetine Market, By Region, From 2027 to 2027 (USD Billion)
  142. Asia-Pacific Bupropion Market, By Region, From 2027 to 2027 (USD Billion)
  143. Asia-Pacific Guanfacine Market, By Region, From 2027 to 2027 (USD Billion)
  144. China Non-Stimulants ADHD Therapeutics Market, By Type, From 2027 to 2027 (USD Billion)
  145. India Non-Stimulants ADHD Therapeutics Market, By Type, From 2027 to 2027 (USD Billion)
  146. Japan Non-Stimulants ADHD Therapeutics Market, By Type, From 2027 to 2027 (USD Billion)
  147. South Korea Non-Stimulants ADHD Therapeutics Market, By Type, From 2027 to 2027 (USD Billion)
  148. Australia Non-Stimulants ADHD Therapeutics Market, By Type, From 2027 to 2027 (USD Billion)
  149. Latin America ADHD Therapeutics Market, By Region, From 2027 to 2027 (USD Billion)
  150. Latin America ADHD Therapeutics Market, By Medication, From 2027 to 2027 (USD Billion)
  151. Latin America Stimulants Market, By Region, From 2027 to 2027 (USD Billion)
  152. Latin America Non-Stimulants Market, By Region, From 2027 to 2027 (USD Billion)
  153. Latin America ADHD Therapeutics Market, By Psychotherapy, From 2027 to 2027 (USD Billion)
  154. Latin America Behavior Therapy ADHD Therapeutics Market, By Region, From 2027 to 2027 (USD Billion)
  155. Latin America Cognitive Behavioral Therapy ADHD Therapeutics Market, By Region, From 2027 to 2027 (USD Billion)
  156. Latin America Interpersonal Psychotherapy ADHD Therapeutics Market, By Region, From 2027 to 2027 (USD Billion)
  157. Latin America Family Therapy ADHD Therapeutics Market, By Region, From 2027 to 2027 (USD Billion)
  158. Latin America ADHD Therapeutics Market, By Education or Training, From 2027 to 2027 (USD Billion)
  159. Latin America Parent Management Training ADHD Therapeutics Market, By Region, From 2027 to 2027 (USD Billion)
  160. Latin America Social Skills Training ADHD Therapeutics Market, By Region, From 2027 to 2027 (USD Billion)
  161. Latin America School-based Interventions ADHD Therapeutics Market, By Region, From 2027 to 2027 (USD Billion)
  162. Brazil ADHD Therapeutics Market, By Medication, From 2027 to 2027 (USD Billion)
  163. Brazil ADHD Therapeutics Market, By Psychotherapy, From 2027 to 2027 (USD Billion)
  164. Brazil ADHD Therapeutics Market, By Education or Training, From 2027 to 2027 (USD Billion)
  165. Argentina ADHD Therapeutics Market, By Medication, From 2027 to 2027 (USD Billion)
  166. Argentina ADHD Therapeutics Market, By Psychotherapy, From 2027 to 2027 (USD Billion)
  167. Argentina ADHD Therapeutics Market, By Education or Training, From 2027 to 2027 (USD Billion)
  168. Mexico ADHD Therapeutics Market, By Medication, From 2027 to 2027 (USD Billion)
  169. Mexico ADHD Therapeutics Market, By Psychotherapy, From 2027 to 2027 (USD Billion)
  170. Mexico ADHD Therapeutics Market, By Education or Training, From 2027 to 2027 (USD Billion)
  171. Latin America Stimulants ADHD Therapeutics Market, By Type, From 2027 to 2027 (USD Billion)
  172. Latin America Amphetamines Market, By Region, From 2027 to 2027 (USD Billion)
  173. Latin America Methylphenidate Market, By Region, From 2027 to 2027 (USD Billion)
  174. Latin America Dextroamphetamine Market, By Region, From 2027 to 2027 (USD Billion)
  175. Latin America Dexmethylphenidate Market, By Region, From 2027 to 2027 (USD Billion)
  176. Brazil Stimulants ADHD Therapeutics Market, By Type, From 2027 to 2027 (USD Billion)
  177. Argentina Stimulants ADHD Therapeutics Market, By Type, From 2027 to 2027 (USD Billion)
  178. Mexico Stimulants ADHD Therapeutics Market, By Type, From 2027 to 2027 (USD Billion)
  179. Latin America Non-Stimulants ADHD Therapeutics Market, By Type, From 2027 to 2027 (USD Billion)
  180. Latin America Atomoxetine Market, By Region, From 2027 to 2027 (USD Billion)
  181. Latin America Bupropion Market, By Region, From 2027 to 2027 (USD Billion)
  182. Latin America Guanfacine Market, By Region, From 2027 to 2027 (USD Billion)
  183. Brazil Non-Stimulants ADHD Therapeutics Market, By Type, From 2027 to 2027 (USD Billion)
  184. Argentina Non-Stimulants ADHD Therapeutics Market, By Type, From 2027 to 2027 (USD Billion)
  185. Mexico Non-Stimulants ADHD Therapeutics Market, By Type, From 2027 to 2027 (USD Billion)
  186. Middle East & Africa ADHD Therapeutics Market, By Region, From 2027 to 2027 (USD Billion)
  187. Middle East & Africa ADHD Therapeutics Market, By Medication, From 2027 to 2027 (USD Billion)
  188. Middle East & Africa Stimulants Market, By Region, From 2027 to 2027 (USD Billion)
  189. Middle East & Africa Non-Stimulants Market, By Region, From 2027 to 2027 (USD Billion)
  190. Middle East & Africa ADHD Therapeutics Market, By Psychotherapy, From 2027 to 2027 (USD Billion)
  191. Middle East & Africa Behavior Therapy ADHD Therapeutics Market, By Region, From 2027 to 2027 (USD Billion)
  192. Middle East & Africa Cognitive Behavioral Therapy ADHD Therapeutics Market, By Region, From 2027 to 2027 (USD Billion)
  193. Middle East & Africa Interpersonal Psychotherapy ADHD Therapeutics Market, By Region, From 2027 to 2027 (USD Billion)
  194. Middle East & Africa Family Therapy ADHD Therapeutics Market, By Region, From 2027 to 2027 (USD Billion)
  195. Middle East & Africa ADHD Therapeutics Market, By Education or Training, From 2027 to 2027 (USD Billion)
  196. Middle East & Africa Parent Management Training ADHD Therapeutics Market, By Region, From 2027 to 2027 (USD Billion)
  197. Middle East & Africa Social Skills Training ADHD Therapeutics Market, By Region, From 2027 to 2027 (USD Billion)
  198. Middle East & Africa School-based Interventions ADHD Therapeutics Market, By Region, From 2027 to 2027 (USD Billion)
  199. Middle East ADHD Therapeutics Market, By Medication, From 2027 to 2027 (USD Billion)
  200. Middle East ADHD Therapeutics Market, By Psychotherapy, From 2027 to 2027 (USD Billion)
  201. Middle East ADHD Therapeutics Market, By Education or Training, From 2027 to 2027 (USD Billion)
  202. Africa ADHD Therapeutics Market, By Medication, From 2027 to 2027 (USD Billion)
  203. Africa ADHD Therapeutics Market, By Psychotherapy, From 2027 to 2027 (USD Billion)
  204. Africa ADHD Therapeutics Market, By Education or Training, From 2027 to 2027 (USD Billion)
  205. Middle East & Africa Stimulants ADHD Therapeutics Market, By Type, From 2027 to 2027 (USD Billion)
  206. Middle East & Africa Amphetamines Market, By Region, From 2027 to 2027 (USD Billion)
  207. Middle East & Africa Methylphenidate Market, By Region, From 2027 to 2027 (USD Billion)
  208. Middle East & Africa Dextroamphetamine Market, By Region, From 2027 to 2027 (USD Billion)
  209. Middle East & Africa Dexmethylphenidate Market, By Region, From 2027 to 2027 (USD Billion)
  210. Middle East Stimulants ADHD Therapeutics Market, By Type, From 2027 to 2027 (USD Billion)
  211. Africa Stimulants ADHD Therapeutics Market, By Type, From 2027 to 2027 (USD Billion)
  212. Middle East & Africa Non-Stimulants ADHD Therapeutics Market, By Type, From 2027 to 2027 (USD Billion)
  213. Middle East & Africa Atomoxetine Market, By Region, From 2027 to 2027 (USD Billion)
  214. Middle East & Africa Bupropion Market, By Region, From 2027 to 2027 (USD Billion)
  215. Middle East & Africa Guanfacine Market, By Region, From 2027 to 2027 (USD Billion)
  216. Middle East Non-Stimulants ADHD Therapeutics Market, By Type, From 2027 to 2027 (USD Billion)
  217. Africa Non-Stimulants ADHD Therapeutics Market, By Type, From 2027 to 2027 (USD Billion)

Please wait. . . . Your request is being processed

FAQ's

How big is the ADHD therapeutics market?

The global ADHD therapeutics market size is estimated to be worth USD 29.56 billion in 2022 and USD 45.68 billion by 2027.

Does this report include the impact of COVID-19 on the ADHD therapeutics market?

The impact of COVID-19 on the ADHD therapeutics market has been analyzed in this report and the post-purchase version of the report includes a complete analysis.

Which segment by psychotherapy treatment type is dominating the ADHD market?

The behavior therapy segment is the most lucrative segment and also accounted for the major share of the global ADHD therapeutics market by psychotherapy treatment type in 2021. 

Which are the companies playing a significant role in the global ADHD market?

Shire plc (Ireland), Neos Therapeutics, Inc. (U.S.), Eli Lilly and Company (U.S.), Pfizer Inc. (U.S.), Alcobra Ltd. (Israel), Supernus Pharmaceuticals, Inc. (U.S.), Noven Pharmaceuticals, Inc. (U.S.), Novartis AG (Switzerland), Johnson & Johnson (U.S.) and Curemark, LLC. (U.S.) are a few of the notable players in the global ADHD therapeutics market.

Related Reports

PURCHASE OPTIONS

excel
$

4255


pdf excel
$

5060


pdf excel powerbi
$

7360


excel
$

2500

What You Get :

  • PDF Report Format.
  • Can be accessible by 1 single user.
  • 6 Months of Free Analyst Support.
  • PDF and Excel Datasheet Formats.
  • Can be accessible upto 2 to 5 users.
  • 1 Year of Free Analyst Support.
  • PDF, Excel and Power BI Dashboard.
  • Can be accessible by unlimited users.
  • 1 Year of Free Analyst Support.
  • Excel Datasheet Format.
  • Customized access as per user request.
  • Upgradable to other licenses.
customer-support
ASK FOR CUSTOMIZATION

Talk to our analyst and get customised report done according to your research needs

tag
INQUIRE FOR DISCOUNT

Check if you can avail any discount. Submit your details and our team will get back to you.

cloud-download
DOWNLOAD FREE SAMPLE

Request to avail a free sample report that reflects this market and its growth.

Access the study in MULTIPLE FORMATS
Purchase options starting from $ 4255

Didn’t find what you’re looking for?
TALK TO OUR TEAM

Find it too expensive?
NO WORRIES!

Click for Request Sample